Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Zutripro is an oral prescription combination cough and cold medication containing hydrocodone bitartrate (an opioid agonist antitussive), chlorpheniramine maleate (a first-generation histamine-1 receptor antagonist), and pseudoephedrine hydrochloride (a sympathomimetic alpha-adrenergic agonist nasal decongestant). It is indicated for the temporary relief of cough and upper respiratory symptoms, including nasal congestion, associated with allergy or the common cold in adults, but carries boxed warnings related to opioid addiction, abuse and misuse, life‑threatening respiratory depression, accidental ingestion (particularly in children), cytochrome P450 3A4–mediated drug interactions, and concomitant use with benzodiazepines or other central nervous system depressants.[1][4][7]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Zutripro.